Topical Bevacizumab for Preventing Recurrent Pterygium

Sponsor
Chulalongkorn University
Study ID
NCT01311960
Phase
PHASE3
Status
Completed

Conditions

  • Anti-VEGF
  • Bevacizumab
  • Pterygium
  • VEGF

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • bevacizumab eye drop 0.05% — DRUG
    bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
  • normal saline 0.9% — DRUG
    normal saline eye drop 0.9% will apply 4 times a day for 3 months.

Study Details

The purpose of this study is to determine whether bevacizumab eye drop is effective in the treatment of recurrent pterygium.

Key Dates

First listed
Mar 10, 2011
Start date
Dec 31, 2010
Status verified
Mar 2011
Primary completion
Mar 31, 2013
Completion
Apr 30, 2013

Study Design

Enrollment
24 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: bevacizumab eye drop
  • Experimental: placebo normal saline eye drop

Primary Outcome Measure

rate of recurrence after primary pterygium removal [ Time Frame: 3 months ]